Parabilis Medicines, Inc. (PBLS)
NASDAQ: PBLS · Real-Time Price · USD
28.53
+0.65 (2.33%)
Nov 6, 2026, 4:00 PM EST - Market closed
Parabilis Medicines Earnings Call Transcripts
Fiscal Year 2026
-
Zolucatetide showed 72.2% ORR at week 32 and 100% disease control among response-evaluable patients starting at 450 mg or higher, with no progressions observed. FDA-aligned plans target PEDESTAL initiation in H1 2027 and top-line data in 2029.
-
The Helicon platform enables targeting of undruggable proteins, with Zolucatetide showing strong efficacy and safety in desmoid tumors and promising early results in FAP and ACP. Phase III trials, pipeline expansion, and a Regeneron partnership are underway, supported by $1.1B in cash.